APA (7th ed.) Citation

Lin, N. U., Guo, H., Yap, J. T., Mayer, I. A., Falkson, C. I., Hobday, T. J., . . . Van den Abbeele, A. D. (2015). Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [ 18 F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). Journal of clinical oncology, 33(24), 2623-2631. https://doi.org/10.1200/JCO.2014.60.0353

Chicago Style (17th ed.) Citation

Lin, Nancy U., et al. "Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [ 18 F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)." Journal of Clinical Oncology 33, no. 24 (2015): 2623-2631. https://doi.org/10.1200/JCO.2014.60.0353.

MLA (9th ed.) Citation

Lin, Nancy U., et al. "Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [ 18 F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)." Journal of Clinical Oncology, vol. 33, no. 24, 2015, pp. 2623-2631, https://doi.org/10.1200/JCO.2014.60.0353.